Asthma Research and Practice: Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms

Ryosuke SoumaKumiya Sugiyama, Hiroyuki MasudaHajime ArifukuKentaro NakanoHiroyoshi WatanabeTomoshige WakayamaShingo TokitaMasamitsu TatewakiHideyuki SatohKenya KoyamaYumeko HayashiFumiya FukushimaHirokuni HirataMasafumi ArimaKazuhiro KurasawaTakeshi Fukuda and Yasutsugu Fukushima

Abstract

Background

The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.

Methods

Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.

Results

Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, p < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = − 0.591X + 89.2 (r2 = 0.299, p < 0.001).

Conclusion

As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Allergy, Asthma & Immunology https://t.co/bz6W0CS4gd, see more https://t.co/CpGiFv6pPL
1hreplyretweetfavorite
Interasma RT @EAACI_HQ: Are you going to #EAACI2019? Tell us what you are most looking forward to ! #EAACI #allergy #immunology #lisbon #research #…
13hreplyretweetfavorite
Interasma RT @ACAAI: Sometimes, an allergist may recommend an elimination diet to help pinpoint the food that you or your child might be sensitive to…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with Chronic Urticaria. Corresp…
13hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma